2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy
| Format: | General Document |
|---|
| _version_ | 1860798083042902016 |
|---|---|
| building | INTELEK Repository |
| collection | Online Access |
| collectionurl | https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection3 |
| copyright | Copyright©PWB2025 |
| country | Malaysia |
| date | 2019-06-20 |
| format | General Document |
| id | 15851 |
| institution | UniSZA |
| internalnotes | Sila masukkan subject wajib Dissertations, Academic. Terima kasih... |
| originalfilename | THE EFFECTS OF POMEGRANATE (PUNICA GRANATUM) EXTRACT IN-VITRO AND IN-VIVO STUDIES TOWARDS DEVELOPMENT OF NON OPIOID SUBSTITUTION THERAPY (MASTER_2019).pdf |
| person | Norhaslinda Binti Ridzwan |
| recordtype | oai_dc |
| resourceurl | https://intelek.unisza.edu.my/intelek/pages/view.php?ref=15851 |
| sourcemedia | Server storage Scanned document |
| spelling | 15851 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=15851 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection3 General Document Malaysia Library Staff (Top Management) Library Staff (Management) Library Staff (Support) Terengganu Faculty of Health Sciences English application/pdf 1.5 Server storage Scanned document Universiti Sultan Zainal Abidin UniSZA Private Access UNIVERSITI SULTAN ZAINAL ABIDIN SAMBox 2.3.4; modified using iTextSharp™ 5.5.10 ©2000-2016 iText Group NV (AGPL-version) Copyright©PWB2025 247 THE EFFECTS OF POMEGRANATE (PUNICA GRANATUM) EXTRACT IN-VITRO AND IN-VIVO STUDIES TOWARDS DEVELOPMENT OF NON OPIOID SUBSTITUTION THERAPY (MASTER_2019).pdf 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy Norhaslinda Binti Ridzwan 2019-06-20 Pomegranate—Therapeutic use Pomegranate (Punica granatum) are the oldest known edible fruit produced in tropical and subtropical regions such as Mediterranean region, Afghanistan, Iran and other countries. Nowadays, there is an increased interest in this fruit as a functional food for health benefits because of its useful in disease prevention and wellness promotion. Studies have demonstrated that anthocyanin is one of the major compounds found in the edible part of pomegranate fruit, which produces high antioxidant activity. Currently, anthocyanin have been reported could induce cognitive improvements, which is related signaling in managing withdrawal symptoms. This study was conducted to investigate the determination of anthocyanin contents; cyanidin 3-glucoside, cyanidin 3, 5-diglucoside, pelargonidin 3-glucoside, pelargonidin 3, 5-diglucoside in pomegranate extracts of 50% aqueous ethanol and aqueous solution using high performance liquid chromatography (HPLC). The potential of pomegranate extract towards a non-opioid substitution therapy in human Glioblastoma Multiforme cancer (U-87) cell line and the spontaneous locomotor activity of morphine and pomegranate extract groups of Sprague Dawley male rats using Morris Water Maze (MWM) method were also studied. The determination and quantification of anthocyanin showed aqueous solution extract using blender method contain higher composition of cyanidin 3-glucoside with 31.60 (12.48) mg/100 g edible portion (e.p), cyanidin 3, 5-diglucoside with 35.31 (14.08) mg/100 g e.p, pelargonidin 3-glucoside with 22.61 (6.28) mg/100 g e.p and pelargonidin 3, 5-diglucoside with 5.30 (8.28) mg/100 g e.p. This indicated that aqueous solution extract of pomegranate contained highest amount of anthocyanin compounds. The determination of safe dosages study observed that the concentrations morphine at 1.60 (0.06) µg/mL and pomegranate extract at 0.44 (0.04) mg/mL gives standard inhibition of 50% (IC50) U-87 cell line, respectively. At the given concentrations above IC50, regulations of µ-opioid receptors (MORs) and adenosine 3,5 cyclic monophosphate (cAMP) levels for both morphine and pomegranate extract on U-87 cell line were evaluated. An optimum concentration of morphine had been chosen at 0.625 µg/mL. This was determine based on significant increment in the MORs and cAMP levels (p<0.05). Meanwhile, an optimum concentration of pomegranate extract was chosen at 0.125 mg/mL. This had been determine by significant decrement in the MORs and cAMP levels (p<0.05). The co-treatment of morphine and pomegranate extract showed a significant decrement (p<0.05) of MORs and cAMP levels as compared to morphine and treated methadone groups. Memory impairment study in male rats Sprague Dawley showed that the morphine treated with pomegranate extract had improve the total swimming distance (cm) and escape time latency (sec) as compared to morphine group (p<0.05). The serum blood from these group also had significantly decrease (p<0.05) level of cAMP responsive element binding protein (CREB) protein and significantly increase (p<0.05) level of brain-derived neurotropin family (BDNF) protein after treated with pomegranate extract. The MWM study showed positive correlation with the levels of CREB and BDNF proteins. As a conclusion, this study provided potency of pomegranate extract as a non-opioid substitution therapy in-vitro and in-vivo studies. Dissertations, Academic Sila masukkan subject wajib Dissertations, Academic. Terima kasih... Pomegranate Extract in Pain Management Punica Granatum And Opioid Withdrawal Non-Opioid Analgesic Development Thesis |
| spellingShingle | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| state | Terengganu |
| subject | Pomegranate—Therapeutic use Dissertations, Academic |
| summary | Pomegranate (Punica granatum) are the oldest known edible fruit produced in tropical and subtropical regions such as Mediterranean region, Afghanistan, Iran and other countries. Nowadays, there is an increased interest in this fruit as a functional food for health benefits because of its useful in disease prevention and wellness promotion. Studies have demonstrated that anthocyanin is one of the major compounds found in the edible part of pomegranate fruit, which produces high antioxidant activity. Currently, anthocyanin have been reported could induce cognitive improvements, which is related signaling in managing withdrawal symptoms. This study was conducted to investigate the determination of anthocyanin contents; cyanidin 3-glucoside, cyanidin 3, 5-diglucoside, pelargonidin 3-glucoside, pelargonidin 3, 5-diglucoside in pomegranate extracts of 50% aqueous ethanol and aqueous solution using high performance liquid chromatography (HPLC). The potential of pomegranate extract towards a non-opioid substitution therapy in human Glioblastoma Multiforme cancer (U-87) cell line and the spontaneous locomotor activity of morphine and pomegranate extract groups of Sprague Dawley male rats using Morris Water Maze (MWM) method were also studied. The determination and quantification of anthocyanin showed aqueous solution extract using blender method contain higher composition of cyanidin 3-glucoside with 31.60 (12.48) mg/100 g edible portion (e.p), cyanidin 3, 5-diglucoside with 35.31 (14.08) mg/100 g e.p, pelargonidin 3-glucoside with 22.61 (6.28) mg/100 g e.p and pelargonidin 3, 5-diglucoside with 5.30 (8.28) mg/100 g e.p. This indicated that aqueous solution extract of pomegranate contained highest amount of anthocyanin compounds. The determination of safe dosages study observed that the concentrations morphine at 1.60 (0.06) µg/mL and pomegranate extract at 0.44 (0.04) mg/mL gives standard inhibition of 50% (IC50) U-87 cell line, respectively. At the given concentrations above IC50, regulations of µ-opioid receptors (MORs) and adenosine 3,5 cyclic monophosphate (cAMP) levels for both morphine and pomegranate extract on U-87 cell line were evaluated. An optimum concentration of morphine had been chosen at 0.625 µg/mL. This was determine based on significant increment in the MORs and cAMP levels (p<0.05). Meanwhile, an optimum concentration of pomegranate extract was chosen at 0.125 mg/mL. This had been determine by significant decrement in the MORs and cAMP levels (p<0.05). The co-treatment of morphine and pomegranate extract showed a significant decrement (p<0.05) of MORs and cAMP levels as compared to morphine and treated methadone groups. Memory impairment study in male rats Sprague Dawley showed that the morphine treated with pomegranate extract had improve the total swimming distance (cm) and escape time latency (sec) as compared to morphine group (p<0.05). The serum blood from these group also had significantly decrease (p<0.05) level of cAMP responsive element binding protein (CREB) protein and significantly increase (p<0.05) level of brain-derived neurotropin family (BDNF) protein after treated with pomegranate extract. The MWM study showed positive correlation with the levels of CREB and BDNF proteins. As a conclusion, this study provided potency of pomegranate extract as a non-opioid substitution therapy in-vitro and in-vivo studies. |
| title | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| title_full | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| title_fullStr | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| title_full_unstemmed | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| title_short | 2019_The Effects of Pomegranate (Punica Granatum) Extract In-Vitro and In-Vivo Studies Towards Development of Non Opioid Substitution Therapy |
| title_sort | 2019_the effects of pomegranate (punica granatum) extract in-vitro and in-vivo studies towards development of non opioid substitution therapy |